Haemonetics Corp

Haemonetics Corp

  • Price (USD)49.06
  • Today's Change-1.27 / -2.52%
  • Shares traded9.00
  • 1 Year change-58.04%
  • Beta0.3225
Data delayed at least 15 minutes, as of Jan 21 2022 21:10 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. It markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.

  • Revenue in USD (TTM)933.83m
  • Net income in USD31.24m
  • Incorporated1985
  • Employees2.71k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Outset Medical Inc91.70m-122.75m1.81bn313.00--4.40--19.70-2.77-2.772.068.710.20053.776.95292,961.70-26.83---29.21--5.13---133.86--9.64-90.750.0677--231.18--7.18------
Fulgent Genetics Inc1.04bn569.33m1.81bn429.003.151.753.161.7519.2419.2434.6534.761.43--9.722,414,664.0077.8233.2591.1738.1280.1974.6654.5439.63----0.01980.001,196.46113.1952,243.55--75.67--
Cytek Biosciences Inc-100.00bn-100.00bn1.90bn462.00--4.72----------3.01------------------------13.74--0.00--60.39--119.11------
Pacific Biosciences of California Inc121.63m-36.96m2.22bn412.00--2.64--18.23-0.2459-0.24590.58353.810.10423.986.80295,218.40-3.17-37.11-3.44-46.5343.9839.54-30.39-74.8619.99-15.360.5159---13.20-3.19134.95---19.16--
Axonics Inc161.94m-76.25m2.28bn416.00--4.66--14.10-1.83-1.833.9010.590.35631.047.31389,274.00-16.78---18.10--63.27---47.09--9.36-8.100.0002--707.06--31.30------
Glaukos Corp294.01m-38.37m2.41bn653.00--4.01--8.19-0.8477-0.84776.3112.830.28563.508.63450,237.40-3.73-6.01-3.94-6.6076.4178.99-13.05-12.377.60-3.740.3697---5.0725.69-880.26---15.27--
Adapthealth Corp2.12bn-42.36m2.43bn8.70k--1.2217.071.15-1.60-1.6018.0715.060.627622.838.55243,119.00-1.87---2.13--21.01---2.98--1.441.580.5278--102.15---657.38------
Haemonetics Corporation933.83m31.24m2.51bn2.71k81.113.5920.472.680.60490.604918.2613.680.58011.596.60344,839.401.943.922.414.9146.6146.023.355.591.315.840.52780.00-11.94-0.8593.85---18.40--
Integer Holdings Corp1.18bn88.45m2.63bn7.50k29.971.9815.562.242.662.6635.4340.350.49075.555.50156,936.403.692.293.942.4727.8929.447.515.191.884.540.32130.00-14.686.05-15.30--2.89--
Patterson Companies, Inc.6.38bn159.84m2.71bn7.80k16.982.6811.290.42441.641.6465.2210.372.246.4013.10817,576.705.58-0.34759.28-0.49220.1121.732.49-0.19960.8125--0.3844--7.691.88126.51-3.43-20.132.93
AtriCure Inc.258.84m45.38m2.82bn750.0066.365.7851.1810.900.92590.92595.8210.630.3921.808.78345,114.706.87-8.447.43-9.3574.6772.6717.53-17.002.9130.380.1215---10.529.74-36.83---17.12--
NuVasive, Inc.1.13bn-25.66m2.99bn2.70k--3.6224.712.65-0.4976-0.497621.8515.950.47121.055.58418,044.40-1.071.55-1.361.8171.3572.62-2.272.572.351.770.51760.00-10.065.31-156.95--0.3312--
Nevro Corp393.88m-108.36m3.00bn843.00--9.39--7.61-3.12-3.1211.359.150.57891.355.54467,231.30-15.92-12.91-20.71-15.3269.8069.17-27.51-17.965.97-2.920.318---7.2339.0719.89--3.77--
Agape ATP Corp1.32m-1.46m3.01bn35.00--703.15--2,277.13-0.0039-0.00390.00350.01140.21530.54099.5637,787.14-23.82---28.05--79.79---110.61--4.27-49.540.00--------------
Merit Medical Systems, Inc.1.05bn43.22m3.14bn5.99k73.023.1024.192.980.76280.762818.5517.950.63632.817.20176,033.202.611.362.971.5244.3643.604.102.171.2013.450.21570.00-3.1112.20-280.57---1.41--
Inmode Ltd322.21m148.40m3.29bn311.0024.838.5522.0610.201.731.733.765.030.89282.7816.611,036,051.0041.14--47.10--85.31--46.07--7.81--0.00--31.81--22.71------
Data as of Jan 21 2022. Currency figures normalised to Haemonetics Corp's reporting currency: US Dollar USD

Institutional shareholders

51.80%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20215.57m10.90%
The Vanguard Group, Inc.as of 30 Sep 20214.76m9.31%
Wellington Management Co. LLPas of 30 Sep 20214.24m8.31%
Neuberger Berman Investment Advisers LLCas of 30 Sep 20213.86m7.55%
SSgA Funds Management, Inc.as of 30 Sep 20211.66m3.25%
Franklin Advisers, Inc.as of 30 Sep 20211.47m2.88%
Westfield Capital Management Co. LPas of 30 Sep 20211.36m2.66%
LGT Capital Partners AG (Investment Management)as of 31 Dec 20211.22m2.38%
Janus Capital Management LLCas of 30 Sep 20211.20m2.36%
Capital Research & Management Co. (Global Investors)as of 30 Sep 20211.13m2.22%
More ▼
Data from 30 Sep 2021 - 31 Dec 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.